This work was funded by Boehringer Ingelheim International GmbH. VW-J, H-JR, and RY are employees of Boehringer Ingelheim. NA has acted as an advisor to AbbVie/Allergan, Boehringer Ingelheim, Echosens, Fibronostics, Gilead, Intercept, Madrigal, Novo Nordisk, Perspectum, Pfizer, and Zydus; received grant/research support from 89Bio, AbbVie/Allergan, Akero, Better Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Corcept, DSM, Galectin, Genentech, Genfit, Gilead, Hepagene, Healio, Intercept, Inventiva, Ionis, Madrigal, Merck, NGM, Noom, NorthSea, Novo Nordisk, Perspectum, Pfizer, Poxel, Viking, and Zydus; and received speaker fees from AbbVie/Allergan, Alexion, Echosens, Eisai, Exelixis, Gilead, Intercept, Perspectum, Salix, and Theratechnologies. ET has received speaker fees from Boehringer Ingelheim, Dr. Falk Pharma GmbH, Novo Nordisk, and Pfizer; and acted as an advisor to Boehringer Ingelheim, Novo Nordisk, and Pfizer. JMS has acted as a consultant to AstraZeneca, Apollo Endosurgery, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, GSK, Intercept Pharmaceuticals, Ipsen, Inventiva Pharma, Madrigal, MSD, NorthSea, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and Siemens Healthineers; received research/grant support from Boehringer Ingelheim, Gilead Sciences, and Siemens Healthcare GmbH; holds stock in AGED Diagnostics and Hepta Bio; and received speaker fees from Boehringer Ingelheim, Echosens, Histoindex, Madrigal, Med Publico GmbH, and Novo Nordisk. JM and TC have nothing to disclose.

Susie Eaton, MBio, of Callisto, OPEN Health Communications (London, UK) provided writing, editorial, and formatting support, which was contracted and funded by Boehringer Ingelheim. The authors were fully responsible for all content and editorial decisions, were involved at all stages of poster development, and have approved the final version.

Presenting author: Jeff McIntyre, Global Liver Institute, Washington, DC, USA; Email: jmcintyre@globalliver.org